Trial Information

Malignancy is the first cause of death in Taiwan. There are around 30,000 people died due to
malignancy every year. Ovarian cancer is the first mortality rate of gynecologic
malignancies. The incidence of ovarian cancer increased in recent 10 years. Ovarian cancer
indeed is a disease that should be respected, however, there were only few of research work
focusing on it in Taiwan.

To study the mechanisms of carcinogenesis of ovarian cancer will help us understand this
disease and develop new strategies of diagnosis and prevention for ovarian cancer in the
future. The present diagnostic methods of malignancy are clinical symptoms, physical
examination, evaluation of tumor markers and instruments. It is a important issue to
diagnose cancer earlier to improve the survival of cancer patients. By the development of
biomedical science, many genes have been identified to be related with the carcinogenesis.
If we can detect the possibility of genetic mutation earlier, we may deal with the suspected
areas of malignancy as soon as possible. To our present knowledge, carcinogenesis of ovarian
cancer has strong correlation with some special genes such as BRCA1 and BRCA2 genes. There
is 1 out of 200 normal population with BRCA1 or BRCA2 gene mutation in the western
countries. The incidences of BRCA1 or BRCA2 gene mutation even increase to 30-50% in the
population of familial ovarian cancer. Women with BRCA1 gene mutation have 80% to get breast
cancer before the age of 70 and 63% of them would get ovarian cancer before the age of 70.
Women with BRCA2 gene mutation have 80% to get breast or ovarian cancer before the age of
70. It seems that the genetic diagnosis of BRCA1/BRCA2 has its clinical practice. The
development of new instrument- denaturing high-performance liquid chromatography (DHPLC) is
to use automated detection to find out the minute or single mutation of nucleotide. It has
been applied to the clinical service by utilizing DHPLC for the genetic diagnosis of BRCA1
and BRCA2 of breast cancer patients in the department of Genetic Medicine of our hospital.
It will become a most powerful tool to establish the database of BRCA1 or BRCA2 gene
mutation of the ovarian cancer patients in Taiwan, when we can use the technique of DHPLC
combining with the direct DNA sequencing.

So we propose this research project. There are two main purposes in this project. First, we
will utilize the new technique of DHPCL with direct DNA sequence to set up the database of
BRCA1 and BRCA2 gene mutation of ovarian cancer patients in Taiwan. We can screen out BRCA1
and BRCA2 gene mutation from high-risk group by this new technique. And then we can provide
these patients suitable genetic consulting and related treatment planning. Second, we would
lie to set up the new technique of DHPLC combining with direct DNA sequencing in the genetic
diagnosis of ovarian cancer patients for the future clinical service in our hospital.